Tirzepatide Delivers 15-20% Weight Loss Versus 12-13% for Semaglutide in Meta-Analysis of GLP-1 Agonists

The meta-analysis aggregated phase 3 data from SURMOUNT-1 and STEP trials plus smaller head-to-head studies, measuring percent body-weight change at 68-72 weeks as the primary endpoint while tracking gastrointestinal adverse-event rates. Tirzepatide's dual GLP-1/GIP agonism yielded an additional 3-7 absolute percentage points of loss, consistent with its longer receptor engagement and greater suppression of caloric intake observed in mechanistic substudies.

Cardiovascular outcome data remain asymmetric: semaglutide carries two large outcome trials (SUSTAIN-6, SELECT) showing 20% MACE reduction, whereas tirzepatide's SURPASS-CVOT is ongoing with readout expected 2025. Cost and access further differentiate the agents; semaglutide lists at roughly 30% lower net price after rebates and offers an oral formulation approved December 2024.

No single agent dominates for every patient; tirzepatide maximizes weight loss magnitude while semaglutide supplies longer-term hard-outcome evidence and route flexibility. Future trials must report absolute event-rate differences and quality-adjusted life-year gains to guide formulary decisions.

Next studies should include direct randomized comparisons with cardiovascular and renal endpoints plus real-world persistence data beyond 2 years.